This Episode is Sponsored by Madrigal Pharmaceuticals: CLDF opted for a Liver Connect program that featured conversations between sizable groups of experts instead of lengthy scientific presentations. How well did it work for panelists?
This Episode is Sponsored by Madrigal Pharmaceuticals: Once we acknowledge the potential for economic, social and medical damage that the increasing trend toward adolescent and pediatric NAFLD will cause, what solutions do we have? Can Liver Health education be effective?
This Episode is Sponsored by Madrigal Pharmaceuticals: What Can We Learn About Health Disparities In NASH Epidemiology and Treatment From the Content of NASH Connect?
This Episode is Sponsored by Madrigal Pharmaceuticals: What does CLDF President Zobair Younossi have to say about Liver Connect, NASH Connect, and the needs of the Fatty Liver community?
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among
